spacer
home > ebr > winter 2002 > investigating biomolecular interactions in neuropathology: the role of spr
PUBLICATIONS
European Biopharmaceutical Review

Investigating Biomolecular Interactions in Neuropathology: The Role of SPR

Understanding the complex biological mechanisms that regulate the function of the brain and central nervous system (CNS) represents a daunting task for life science and drug discovery researchers. The processes underlying the development of the CNS, how we sense and react to our environment and why we suffer from neurodegenerative diseases, are all dictated by cascades of biomolecular interactions. These processes are mediated by a variety of signalling molecules; how and where these molecules interact with their targets is a fundamental focus of research. Therefore new technologies based on surface plasmon resonance (SPR), designed specifically for the study of biomolecular binding events, can be powerful and key tools in neuroscience. Indeed, they are already bringing major benefits to research areas such as nerve cell growth, the connections they make with other nerve cells, the way in which messages are communicated and their response to endogenous and exogenous agents.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Stefan Löfås, Vice President and Chief Scientific Officer of Biacore AB Dr Stefan Löfås holds a PhD and a BSc in Organic Chemistry. Having worked for the company since 1985, he has gained extensive technical and scientific experience in the development and commercialisation of bioanalytical instrumentation at Biacore AB.
Dr Löfås has been intensively involved in the development of Biacore's sensor chip chemistry and applications and was recently appointed Chief Scientific Officer with responsibility for technical development projects, external scientific collaborations and technical aspects of the IPR portfolio. Prior to this role, Dr Löfås was Director of Biacore's biochemistry and chemistry department within R&D.

spacer
Stefan Löfås
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Surge of Indian biosimilars market forecast in 2019

16th April 2019: New data from CPhI shows that, despite ongoing reputational challenges, India’s biologics market is set for robust growth in 2019 driven by biosimilars production. The India specific findings from CPhI’s bio league tables predict strong ‘bio growth potential’ in India throughout 2019 in the build-up to the 13th edition of CPhI India 2019, which will take place at the India Expo Centre in Delhi NCR.
More info >>

White Papers

Pharmaceutical Companies: Outsourcing Combination Product Manufacturing

Phillips-Medisize

Combination products are therapeutics that combine two or more products (drug/device, biologics/device, biologics/drugs, or drug/device/biologics), regulated and sold as a single unit. Examples of combination products include drug-coated implantable devices, drugs packaged with delivery devices in medical kits, and drugs and devices packaged separately but intended to be used together.
More info >>

 
Industry Events

PDA Europe Annual Meeting 2019

24 June 2019, Hilton Amsterdam

Featuring updates from international regulatory agencies as well as industry, this promises to become another highlight in the 2019 event calendar and is a meeting not to be missed!
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement